Synergen Inc.

The shortfall in manufacturing capacity for therapeutic proteins threatens the market value of biotechs and competitive positions among innovators, marketers, and service providers. by Roland Andersso

The first approved sepsis drug could save hundreds of thousands of lives, and help Lilly become perhaps the first major drug firm to survive, as an independent, the patent expiration of its most impor

Crises that would have crushed other biotech firms spurred a faithful few investors to refinance Amylin. The fresh start may help the firm's star rise again. by Deborah Erickson Unceremoniously dumped

A "medicinal chemistry strike force" After Amgen Inc. acquired Synergen Inc. following that company's failed Phase III sepsis trial for Antril [See Deal] , it immediately set about assembling